Integrins in cancer: biological implications and therapeutic opportunities.

Integrins in cancer: biological implications and therapeutic opportunities.
复制标题

DOI:
10.1038/nrc2748
复制
发表时间:
2010-01
影响因子:
78.5
通讯作者:
Cheresh, David A.
Cheresh, David A.
中科院分区:
医学1区
文献类型:
--
作者:
Desgrosellier, Jay S.;Cheresh, David A.

文献摘要

参考文献

被引文献

相似文献

细胞粘附受体的整合素家族调节对实体瘤的发生、进展和转移至关重要的多种细胞功能。整合素在影响肿瘤进展的几种细胞类型中的重要性使其成为癌症治疗的吸引人的靶点。整合素拮抗剂,包括αvβ3和αvβ5抑制剂西仑吉肽,在II期临床试验中显示出令人鼓舞的活性,西仑吉肽目前正在胶质母细胞瘤患者中进行III期试验。这些令人兴奋的临床进展强调需要确定整合素拮抗剂如何影响肿瘤及其微环境。
The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumours. The importance of integrins in several cell types that affect tumour progression has made them an appealing target for cancer therapy. Integrin antagonists, including the αvβ3 and αvβ5 inhibitor cilengitide, have shown encouraging activity in Phase II clinical trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma. These exciting clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment.
DOI: 10.1126/science.7512751
发表时间: 1994-04-22
期刊: SCIENCE
影响因子: 56.9
作者:
BROOKS, PC;CLARK, RAF;CHERESH, DA
通讯作者: CHERESH, DA
DOI: 10.1172/jci118227
发表时间: 1995-10-01
影响因子: 15.9
作者:
BROOKS, PC;STROMBLAD, S;CHERESH, DA
通讯作者: CHERESH, DA
DOI: 10.1158/0008-5472.can-05-2827
发表时间: 2005-12-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Bertotti, A;Comoglio, PM;Trusolino, L
通讯作者: Trusolino, L
DOI: 10.1038/ncb1530
发表时间: 2007-02-01
影响因子: 21.3
作者:
Asselin-Labat, Marie-Liesse;Sutherland, Kate D.;Visvader, Jane E.
通讯作者: Visvader, Jane E.
DOI: 10.1073/pnas.2234372100
发表时间: 2003-11-25
影响因子: 11.1
作者:
Bakewell, SJ;Nestor, P;Weilbaecher, KN
通讯作者: Weilbaecher, KN